"GBA1 #parkinsons safety results out for randomized, double-blind, placebo-controlled trial in 40 folks. GBA1 encodes enzyme glucocerebrosidase (GCase). Trial of disease-modifying therapy called LTI-291; allosteric activator GCase, increases activity. https://t.co/2gm3AzrpmE"